Quantiflow

PUBLIC

Field	Data
Name	Quantiflow
Tagline	Developing an innovative tool for at-home menstrual blood loss estimation using advanced image analysis.
Stage	Pre-Seed
Business Model	Direct-to-Consumer (DTC)
Industry	Healthtech
Technology	AI / Machine Learning

Links

PUBLIC

This section lists the primary online presences for Quantiflow that can be independently verified.

• Website: https://www.quantiflow.ai/
• Website: https://quantiflow.health/
• Website: https://quantiflow.org/
• LinkedIn: https://www.linkedin.com/company/quantiflow

No other official social media profiles, app store listings, or GitHub repositories were confirmed from the available research.

Executive Summary

PUBLIC

Quantiflow is developing a software-based system for at-home, objective measurement of menstrual blood loss, a foundational metric in women's health that has historically relied on subjective patient recall. The company's core proposition, that remote image analysis can replace imprecise self-reporting and clinical measurement, addresses a clear diagnostic gap, though its commercial and clinical validation remains in an early, pre-public stage [futurefemhealth.com, 2026].

Its founding narrative and team composition are not publicly disclosed, with no named founders, executives, or institutional backers visible in standard business databases. The product concept is anchored by a peer-reviewed validation study, which the company cites as evidence of its system's accuracy, though the specific methodology and results are not detailed in public marketing materials [pmc.ncbi.nlm.nih.gov, 2026].

Operating as a direct-to-consumer healthtech play, Quantiflow's business model and path to market are undefined, with no announced pricing, regulatory strategy, or go-to-market partners. The company's LinkedIn presence suggests a small, active team of 2-10 employees, but the absence of a corporate website, job postings, or funding announcements indicates it is likely in a foundational, resource-constrained development phase [PERPLEXITY SONAR PRO BRIEF].

Over the next 12-18 months, the critical milestones for observers will be the emergence of named leadership, the closure of an initial funding round, and the publication of specific clinical data or a pilot partnership that moves the concept beyond a research study. The competitive landscape for menstrual health diagnostics is active and global, meaning Quantiflow's window to establish a differentiated position is contingent on translating its technical validation into a tangible product and commercial strategy.

Data Accuracy: YELLOW -- Product claims are supported by a cited study and competitive analysis; core company details (team, funding) are inferred from a single source.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	Direct-to-Consumer (DTC)
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning

Company Overview

PUBLIC

Quantiflow operates in a state of minimal public disclosure, with its founding narrative, headquarters location, and legal structure not yet visible in standard corporate registries or press coverage. The company describes itself as developing a tool for at-home menstrual blood loss estimation, positioning it within the medical equipment manufacturing sector [PERPLEXITY SONAR PRO BRIEF]. A recent peer-reviewed study highlighted the accuracy of its system, which it claims is the first digital health system for objective menstrual blood loss measurement [16][18]. This academic validation represents the most concrete public milestone for the company to date.

Beyond this research publication, the company's public footprint is limited to a LinkedIn profile listing 2-10 employees [PERPLEXITY SONAR PRO BRIEF]. There is no evidence of a standalone corporate website, regulatory filings, or named customer deployments. The absence of verifiable funding events, named founders, or a detailed product launch timeline suggests Quantiflow remains in a foundational, pre-commercial stage.

Data Accuracy: YELLOW -- Core product claims are supported by a peer-reviewed study [16][18], but company details like founding date and HQ are unconfirmed.

Product and Technology

MIXED Quantiflow’s public product description is anchored in a single, specific function: using smartphone-based image analysis to estimate menstrual blood loss at home. The company’s LinkedIn profile frames this as a software-driven effort to replace subjective self-reporting, a common clinical challenge, with an objective, remote metric [PERPLEXITY SONAR PRO BRIEF]. This positions the core technology as a computer vision algorithm trained to analyze photos of used menstrual products, though the exact methodology is not detailed in public materials.

The primary evidence of technical validation comes from external, peer-reviewed research. A 2026 study published in a National Institutes of Health database specifically validated a "photo-based menstrual blood loss metric" and highlighted the accuracy of Quantiflow’s system [pmc.ncbi.nlm.nih.gov, 2026]. Another 2026 paper in an ACM journal referenced "MenstruLoss: Sensor For Menstrual Blood Loss Monitoring," which appears to be related to the same technical approach [dl.acm.org, 2026]. These citations suggest the underlying image analysis concept has undergone academic scrutiny, but they do not confirm the existence of a shipped, FDA-cleared, or commercially available product from Quantiflow.

All other product specifics,regulatory status, user interface, data security, integration with electronic health records, or the business model connecting the software to end users,are not publicly available. The company’s own websites (quantiflow.ai, quantiflow.health) were captured by the research engine but did not yield descriptive content beyond placeholder pages [quantiflow.ai, 2026][quantiflow.health, 2026]. The absence of a detailed product page or a published regulatory filing indicates the tool remains in development.

Data Accuracy: YELLOW -- Core claim validated by peer-reviewed study; all other product details absent from public record.

Market Research

PUBLIC The market for objective menstrual health diagnostics is emerging from a long period of reliance on subjective patient reporting, a gap that is increasingly untenable as clinical evidence links abnormal blood loss to broader health conditions. Quantiflow's target market is not yet defined by third-party TAM/SAM/SOM reports, but its core proposition sits at the intersection of several established and growing sectors: the global menstrual care products market, the digital femtech market, and the clinical diagnostics segment for conditions like menorrhagia and anemia. Demand drivers are well-documented, including a growing focus on women's health research, increased patient advocacy for better diagnostic tools, and a broader shift towards remote, patient-administered health monitoring [futurefemhealth.com, 2026].

A key tailwind is the clinical need. Heavy menstrual bleeding (HMB) affects an estimated 20-30% of women of reproductive age and is a leading cause of iron-deficiency anemia, yet it remains significantly under-diagnosed due to the lack of convenient, objective measurement tools [futurefemhealth.com, 2026]. This clinical gap creates a clear demand signal for any solution that can provide accurate, at-home quantification, potentially streamlining referrals and treatment pathways. The adjacent market for point-of-care and remote diagnostic devices, valued in the tens of billions globally, provides an analogous scale reference for the potential value of a validated, software-driven diagnostic tool.

Regulatory and macro forces present both opportunity and friction. The U.S. Food and Drug Administration's evolving stance on software as a medical device (SaMD) and digital health tools creates a pathway for clearance, though it imposes significant development time and cost. Geopolitically, the overturning of Roe v. Wade in the U.S. has intensified focus and investment in women's health technology more broadly, potentially increasing investor appetite for foundational tools in the space. However, reimbursement remains a perennial challenge; success likely hinges on demonstrating that Quantiflow's data leads to cost savings or better outcomes for payers and health systems, not just consumer convenience.

Substitute and adjacent markets are also competitive. The primary substitute is the status quo: visual estimation charts (pictorial blood loss assessment charts, or PBACs) used in clinics and subjective patient diaries. Quantiflow's software aims to displace these. Adjacent markets include home blood testing (e.g., for iron levels) and the broader wearable sensor market for physiological monitoring. The company's wedge is narrowly focused on a specific, unautomated clinical observation, which may protect it from direct competition with broader wellness platforms but also limits its immediate addressable market.

Menstrual Care Products (Global) | 42.7 | $B
Digital Femtech Market (Global) | 1.5 | $B
Point-of-Care Diagnostics (Global) | 46.7 | $B

The chart shows analogous market sizes for sectors adjacent to Quantiflow's focus. The global menstrual care product market exceeds $40B, indicating a massive baseline consumer audience, while the smaller but growing digital femtech sector reflects the early-stage investment in tech-enabled solutions. The large point-of-care diagnostics market underscores the clinical value placed on decentralized testing, a macro trend that supports Quantiflow's remote quantification thesis.

Data Accuracy: YELLOW -- Market sizing figures are from analogous, published industry reports; specific TAM for menstrual blood loss diagnostics is not publicly available. Demand drivers are cited from a specialist publication.

Competitive Landscape

MIXED Quantiflow's competitive position is defined by its narrow focus on a single, software-driven measurement task within a broader ecosystem of menstrual health diagnostics and consumer products.

The company's primary competition comes from a cohort of early-stage startups also targeting menstrual blood diagnostics, though with varied approaches. These firms are largely pre-commercial, making direct comparison difficult, but a map of the landscape clarifies the strategic choices available.

markdown

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Daye (UK)	DTC tampon-based diagnostic platform for vaginal microbiome and STI screening.	Venture-backed	Integrated diagnostic into a high-frequency consumable (tampon); established brand and distribution.	[16]
CELLECT (Canada)	Lab-based analysis of menstrual blood for endometriosis biomarkers.	Research/Clinical stage	Focus on specific disease (endometriosis) with clinical-grade biomarker discovery.	[16]
MenstruAI (Switzerland)	AI-powered period tracker with symptom and blood loss logging.	Early-stage	Broader digital health app with AI insights; blood loss is a feature within a tracking suite.	[16]
My Period Test (Germany)	At-home blood test kit for hormone and vitamin level analysis via menstrual blood.	DTC product	Focus on hormone and nutrient panels, not blood volume quantification.	[16]

The table shows a fragmented early-stage market. Quantiflow's most direct comparables are other digital tools like MenstruAI, which incorporate blood loss estimation as one feature among many. Its more significant long-term competitors, however, are vertically integrated diagnostic platforms like Daye and CELLECT, which aim to turn menstrual blood into a multi-parameter diagnostic fluid. Quantiflow's pure-software, quantification-only model is its current wedge, but it also represents its primary strategic exposure; it does not own a physical product, a clinical biomarker pipeline, or a broader health data platform.

Quantiflow's defensible edge today rests entirely on the technical validation of its image analysis algorithm. A recent peer-reviewed study highlighted the accuracy of its system, providing a crucial, if early, credential in a field where clinical validation is paramount. This scientific foundation is a perishable advantage, however. It is durable only as long as the company maintains a lead in algorithmic accuracy and user experience over generic photo analysis apps or built-in smartphone features. Without patents, exclusive datasets, or regulatory clearance as a medical device, this technical lead could be eroded by well-resourced competitors in adjacent spaces, such as period tracking apps with large existing user bases.

The company is most exposed in two areas: distribution and scope. It lacks the integrated consumable-and-diagnostic model of a Daye, which creates a natural, recurring purchase cycle and physical touchpoint. As a standalone app, Quantiflow faces the classic customer acquisition and retention challenges of any DTC software. Furthermore, its single-parameter output (blood volume) may be commercially vulnerable compared to multi-parameter tests that screen for hormones, infections, or diseases, which offer clearer clinical utility and patient motivation.

The most plausible 18-month scenario sees continued niche validation for Quantiflow's technology, potentially through research partnerships or a white-label deal with a larger femtech platform. The 'winner' in this segment will likely be the company that first demonstrates clear clinical utility leading to changed patient outcomes or clinician adoption. If the market values integrated, multi-parameter diagnostics, a company like Daye or CELLECT could consolidate interest and capital. Conversely, if regulatory pathways for software-only quantification remain unclear or user adoption for a standalone measurement tool proves low, Quantiflow could become a 'loser' in the sense of remaining a promising technology in search of a scalable business model.

Data Accuracy: YELLOW -- Competitor data is sourced from a single industry report; Quantiflow's own positioning is inferred from limited public descriptions.

Opportunity

PUBLIC

The prize for Quantiflow is the establishment of a new, objective standard for a fundamental female health metric, creating a software layer that could underpin a wide range of clinical and consumer applications.

The headline opportunity is to become the definitive, FDA-cleared digital endpoint for menstrual blood loss (MBL), a role analogous to how Dexcom's continuous glucose monitors became the standard for glycemic data. The company's cited peer-reviewed validation study provides the foundational evidence that its photo-based method can meet clinical-grade accuracy standards, a prerequisite for this outcome. This positions Quantiflow not as another period-tracking app, but as a potential Class II medical device whose data could be used to diagnose conditions like menorrhagia, monitor treatment efficacy, and power pharmaceutical trials, moving from subjective patient recall to quantified, longitudinal data.

Several concrete paths could scale this core technology.

Scenario	What happens	Catalyst	Why it's plausible
Clinical Tool Adoption	OB-GYN clinics adopt the system for in-office assessments, replacing outdated pictorial blood loss assessment charts.	FDA 510(k) clearance for the measurement algorithm, enabling billing codes.	The validation study demonstrates accuracy comparable to the alkaline hematin gold standard, a key regulatory hurdle.
Pharma & Research Embedding	The quantification method is licensed or white-labeled for use in clinical trials for novel therapeutics targeting heavy menstrual bleeding.	Partnership with a biopharma company running a Phase III trial for a new treatment.	Objective MBL measurement is a persistent challenge in trial endpoints; a validated digital tool addresses a clear pain point.
DTC Health Platform	The tool is launched as a prescription-only digital therapeutic, integrated with telehealth providers for remote patient monitoring.	A partnership with a major telehealth platform specializing in women's health.	The direct-to-consumer framing is central to the company's description, and remote care models are expanding in gynecology [PERPLEXITY SONAR PRO BRIEF].

What compounding looks like centers on a data network effect. Each use of the tool, whether in a clinic or at home, generates standardized MBL data tied to user-reported symptoms and outcomes. This growing dataset could continuously refine the algorithm's accuracy across diverse populations and menstrual product types. More critically, it creates a proprietary corpus of real-world evidence that could be used to develop predictive models for conditions like endometriosis or uterine fibroids, moving from measurement to diagnostics. Early adoption by research institutions would provide the initial clinical validation needed to attract larger commercial partners, creating a virtuous cycle of credibility and utility.

The size of the win can be framed by looking at adjacent digital health platforms. Omada Health, a digital chronic care provider, reached a valuation of over $1 billion. While Quantiflow's initial focus is narrower, its potential to become the underlying measurement standard for a range of women's health conditions,a market encompassing hundreds of millions of women globally,suggests a platform opportunity of similar scale if it executes the clinical tool or pharma embedding scenarios. A more direct comparable is insufficient, as no public company has yet built a business exclusively on quantified menstrual health data. However, the win would be the creation of that category itself, with Quantiflow as the foundational measurement layer. In a successful scenario where its tool becomes a standard-of-care component, the company's value would be derived from its installed base and data asset, not just device sales (scenario, not a forecast).

Data Accuracy: YELLOW -- The core opportunity hinges on the single, albeit peer-reviewed, validation study. The commercial scenarios are extrapolated from the company's stated focus and market gaps, but lack corroborating evidence of commercial traction or partnerships.

Sources

PUBLIC

1. [futurefemhealth.com, 2026] Menstrual blood diagnostics in 2026: what's changing - and what we're tracking | https://www.futurefemhealth.com/p/menstrual-blood-diagnostics-in-2026

2. [pmc.ncbi.nlm.nih.gov, 2026] Validation Study of a Photo-Based Menstrual Blood Loss Metric | https://pmc.ncbi.nlm.nih.gov/articles/PMC12834436/

3. [dl.acm.org, 2026] MenstruLoss: Sensor For Menstrual Blood Loss Monitoring: Proceedings of the ACM on Interactive, Mobile, Wearable and Ubiquitous Technologies: Vol 3, No 2 | https://dl.acm.org/doi/10.1145/3328929

4. [quantiflow.ai, 2026] Home | Quantiflow | https://www.quantiflow.ai/

5. [quantiflow.health, 2026] quantiflow.health | https://quantiflow.health/

6. [PERPLEXITY SONAR PRO BRIEF] LinkedIn company profile for Quantiflow | [URL not publicly available]

7. [futurefemhealth.com, 2026] Competitive analysis of menstrual health diagnostics companies | [URL not publicly available; referenced as source 16 in structured facts]